Latest1 information on COVID-19
©2022 Stanford Medicine
Dexamethasone Therapy in VLBW Infants at Risk of CLD
Not Recruiting
Trial ID: NCT00011362
Purpose
Infants who are on breathing support are often treated with steroids (dexamethasone);
however, the best timing of therapy is not known. This trial looked at the benefits and
hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in
premature infants.
Official Title
Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD)
Stanford Investigator(s)
Eligibility
Inclusion criteria:
- 501 to 1500 grams
- 13 to 15 days old
- Respiratory-index score of greater than or equal to 2.4 that had been increasing or
minimally decreasing during the previous 48 hours or a score of greater than or equal
to 4.0 even if there had been improvement during the preceding 48 hours
Exclusion criteria:
- Received glucocorticoid treatment after birth
- Had evidence or suspicious signs of sepsis as judged by the treating physician
- Major congenital anomaly of the cardiovascular, pulmonary, or central nervous system
Intervention(s):
drug: Dexamethasone Early
drug: Dexamethasone Late
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305